R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership ...
pharmaphorum

Aviceda raises $207.5m for eye drug, and other financings

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) into pivotal testing. The ...
Seeking Alpha

CHGCF Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Medical Dialogues

Roche Expands AI Capabilities with 2,100+ Nvidia Chips to Accelerate Drug Development

Berlin: Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than ...

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

Alebund Pharmaceuticals ("Alebund" or the "Company"), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the "Agreements") ...
Investing

Chugai Pharmaceutical Co., Ltd. (4519)

View today's Chugai Pharmaceutical Co., Ltd. stock price and latest 4519 news and analysis. Create real-time notifications to follow any changes in the live stock price.